Search results
Results from the WOW.Com Content Network
Romosozumab is used for osteoporosis to decrease the risk of fractures. [10] Two trials found that it reduced the rate of vertebral fracture. In one, there was a 73% lower risk of vertebral fracture after one year, and the benefit was maintained after a second year of taking denosumab.
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, [1] [2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).
Bazedoxifene is used in the prevention of postmenopausal osteoporosis. [5] Osteoporosis represents a major public health concern, especially as the number of postmenopausal women continues to rise. As a result, the need for innovative treatments has become increasingly important.
Raloxifene is used for the treatment and prevention of osteoporosis in postmenopausal women. [11] It is used at a dosage of 60 mg/day for both the prevention and treatment of osteoporosis. [12] In the case of either osteoporosis prevention or treatment, supplemental calcium and vitamin D should be added to the diet if daily intake is inadequate ...
For premium support please call: 800-290-4726 more ways to reach us
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
The drug is one of only two treatments that help to promote bone formation, and the first to reduce bone loss at the same time. First osteoporosis drug of its kind for more than a decade approved ...
Zoledronic acid is used for the treatment of osteoporosis in men and post-menopausal women at increased risk of fracture. [13] [14] In 2007, the US Food and Drug Administration (FDA) approved zoledronic acid for the treatment of postmenopausal osteoporosis. [7] [15]